Showing 104 news articles about Injectable & long-acting PrEP

Filters Content type: Editors' picks Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Injectable & long-acting PrEP

Uganda to roll out injectable HIV drug

Editor's pick
Monitor
30 October 2023
Injectable & long-acting PrEP

Community Manifesto for HIV Long-Acting Injectable PrEP in Europe

Editor's pick
EATG
20 October 2023
Injectable & long-acting PrEP

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

Editor's pick
Gilead Sciences press release
19 October 2023
Injectable & long-acting PrEP

PrEPster at The Love Tank joins community call for injectable PrEP

Editor's pick
Prepster
17 October 2023
Injectable & long-acting PrEP

A shot prevents HIV, but those most in need struggle to access care

Editor's pick
Washington Post
21 September 2023
Injectable & long-acting PrEP

European Commission authorises ViiV Healthcare’s Apretude (cabotegravir long-acting and tablets) for HIV prevention

Editor's pick
ViiV Healthcare
19 September 2023
Injectable & long-acting PrEP

Malaysia Approves First Long-Acting Injectable HIV Prevention Drug

Editor's pick
CodeBlue
15 September 2023
Injectable & long-acting PrEP

Study: Price of long-acting PrEP ‘unrealistic’ for population-level HIV control

Editor's pick
Healio
11 September 2023
PrEP policies & guidelines

US: Insurers must cover injectable HIV prevention drug — unless courts void mandate

Editor's pick
NBC News
24 August 2023
Injectable & long-acting PrEP

MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA

Editor's pick
MSF Access Campaign
20 August 2023
Injectable & long-acting PrEP

Pharma Pricing Secrecy Runs Amok

Editor's pick
Health GAP (Global Access Project)
20 August 2023
Injectable & long-acting PrEP

ViiV Healthcare’s cabotegravir for HIV prevention receives positive CHMP opinion from European Medicines Agency

Editor's pick
ViiV press release
25 July 2023
Injectable & long-acting PrEP

HIV prevention shots and vaginal rings – this is why South African pilots have not yet started

Editor's pick
Spotlight
29 June 2023
Injectable & long-acting HIV treatment

Going Long

Editor's pick
POZ
26 June 2023
Injectable & long-acting PrEP

The anti-HIV injection will be made in South Africa. It could cost between R600 and R800 a pop

Editor's pick
Bhekisisa
9 May 2023
Injectable & long-acting PrEP

Pharmaceutical corporation ViiV must provide transparency on life-saving HIV-prevention drug

Editor's pick
Médecins Sans Frontières
31 March 2023
Injectable & long-acting PrEP

Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine

Editor's pick
Medicines Patent Pool
30 March 2023
Injectable & long-acting PrEP

Cabotegravir long-acting for PrEP registrations continue in Sub-Saharan Africa

Editor's pick
ViiV press release
29 March 2023
Injectable & long-acting PrEP

Black Gay Men and Trans Women Are Well Protected by Injectable PrEP

Editor's pick
POZ
21 March 2023
Injectable & long-acting PrEP

Long-Acting CAB for PrEP Acceptable, Safe in Adolescent Female Africans

Editor's pick
NATAP
27 February 2023
Injectable & long-acting PrEP

Modeling study shows that long-acting injectable cabotegravir has the potential to significantly reduce new HIV infections

Editor's pick
Clinton Health Access Initiative
23 February 2023
Injectable & long-acting PrEP

Large Benefit With Long-Acting PrEP in Black People, but Some HIV Risk Persists

Editor's pick
MedPage Today
22 February 2023
Injectable & long-acting PrEP

Study suggests side-effects and costs are biggest concerns for users of PrEP

Editor's pick
Medical Xpress
1 February 2023
PrEP policies & guidelines

US: Why Are We Delaying Coverage Of New HIV Prevention?

Editor's pick
Health Affairs
26 January 2023